Cryoablation Within the Evolving Paradigm of Multidisciplinary Breast Cancer Treatment De-Escalation.

Authors

Amanda L Yao, Robert C Ward, Elizabeth H Dibble

Published in

Clinical breast cancer. Volume 26. Issue 9. Pages 84-90. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Treatment de-escalation is increasingly shaping the management of breast cancer, aiming to reduce treatment intensity, minimize toxicity, and improve quality-of-life outcomes without compromising effectiveness and survival. Breast cancer cryoablation, a minimally invasive image-guided percutaneous technique that destroys tumor cells through controlled freezing and thawing, has emerged as an alternative to surgery for select patients with early-stage disease. Support for this approach has grown following recent prospective trials demonstrating its safety and efficacy, US Food and Drug Administration approval of the ProSense Cryoablation System for early-stage low-risk breast cancers in women 70 years of age and older, and inclusion of breast cancer cryoablation in updated American Society of Breast Surgeons treatment guidelines. In this review, we summarize the mechanistic rationale, clinical evidence, and practical considerations for clinical adoption of breast cancer cryoablation in the evolving paradigm of treatment de-escalation.

PMID:
42603547
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.